The influence of glucagon on myocardial mechanics of papillary muscles obtained from patients with chronic congestive heart failure

  • B. E. Strauer
Short Communication
Received:

Summary

The influence of glucagon on the inotropic state of the myocardium was studied in the isolated ventricular muscle of patients with chronic congestive heart failure. Under controlled experimental conditions glucagon causes an increase of the velocity of shortening, of the rate of tension development, of the maximal isometric tension (P0) and of the calculated maximal velocity of shortening (Vmax). The results give evidence for a positive inotropic effect of glucagon on the isolated, human ventricular myocardium of patients with chronic congestive heart failure.

Key-words

Glucagon Myocardial Contractility Human Papillary Muscles Chronic Congestive Heart Failure 
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Avenhaus, H., Lüderitz, B., Strauer, B. E., Boite, H.-D., Riecker, G.: Kardiale Wirkungen von Gluoagon. Dtsch. med. Wschr.96, 702–707 (1971).Google Scholar
  2. 2.
    Brogan, E., Kozonis, M. C., Overy, D. C.: Glucagon therapy in heart failure. Lancet1969 I, 482–484.Google Scholar
  3. 3.
    Glick, G., Parmley, W. W., Wechsler, A. S., Sonnenblick, E. H.: Glucagon: its enhancement of cardiac performance in cat and dog and persistance of its inotropic action despite beta receptor blockade with propranolol. Circulat. Res.22, 789–799 (1968).Google Scholar
  4. 4.
    Gold, H. K., Prindle, K. H., Levey, G. S., Epstein, St. E.: Effects of experimental heart failure on the capacity of glucagon to augment myocardial contractility and activate adenyl cyclase. J. clin. Invest.49, 999–1006 (1970).Google Scholar
  5. 5.
    Lucchesi, B. R.: Cardiac actions of glucagon. Circulat. Res.22, 777–787 (1968).Google Scholar
  6. 6.
    Manchester, J. H., Parmely, W. W., Matloff, J. M., Leidtke, A. J., La Raia, P. J., Herman, M. V., Sonnenblick, E. H., Gorlin, R.: Effects of glucagon on myocardial oxygen consumption and coronary blood flow in man and dog. Circulation11, 579–588 (1970).Google Scholar
  7. 7.
    Murtagh, J. G., Binnion, P. F., Lal, S., Hutchison, K. J., Fletcher, E.: Hemodynamic effects of glucagon. Brit. Heart J.32, 307–315 (1970).Google Scholar
  8. 8.
    Nord, H. J., Fontanes, A. L., Williams, J. F.: Treatment of congestive heart failure with glucagon. Ann. intern. Med.72, 649–653 (1970).Google Scholar
  9. 9.
    Rowe, G. G.: Systemic and coronary hemodynamic effects of glucagon. Amer. J. Cardiol.25, 670–674 (1970).Google Scholar
  10. 10.
    Sonnenblick, E. H.: Implications of muscle mechanics in the heart. Fed. Proc.21, 975–990 (1962).Google Scholar
  11. 11.
    Williams, J. F., Childress, R. H., Chip, J. N., Border, J. F.: Hemodynamic effects of glucagon in patients with heart disease. Circulation39, 38–47 (1969).Google Scholar

Copyright information

© Springer-Verlag 1971

Authors and Affiliations

  • B. E. Strauer
    • 1
  1. 1.Department of Medicine, Division of CardiologyUniversity of GöttingenGermany

Personalised recommendations